Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90033


Purpose:

This phase I trial is studying the side effects and best dose of decitabine in treating patients with advanced solid tumors that have not responded to previous treatment. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die


Study summary:

PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose of decitabine in patients with advanced solid tumors. II. Determine the toxic effects of this drug in these patients. III. Determine the dose of this drug with biologic activity in these patients. IV. Determine the pharmacokinetics of this drug in these patients. V. Determine clinical response to this drug in these patients. OUTLINE: This is a dose-escalation, multicenter study. Patients receive decitabine IV over 30 minutes on days 1-5 weekly for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of decitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 2 weeks.


Criteria:

Inclusion Criteria: - Diagnosis of advanced metastatic solid tumor for which all standard therapy has failed, including, but not limited to the following: - Stage III or IV melanoma - Mucosal melanoma allowed - No resectable stage III melanoma - Bladder cancer - Breast cancer - No active symptomatic CNS disease - No radiographically evident cerebral edema - Hormone receptor status: - Not specified - Male or female - Performance status - ECOG 0-1 - Hemoglobin at least 9.0 g/dL - Platelet count at least 100,000/mm^3 - WBC at least 3,500/mm^3 - Absolute granulocyte count at least 1,500/mm^3 - No coagulation disorders - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - SGOT and SGPT less than 2.5 times ULN - Hepatitis B surface antigen negative - Hepatitis C antibody negative - Creatinine no greater than 1.5 times ULN - No major cardiovascular system illness - No major respiratory system illness - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - HIV negative - No major systemic infection - At least 1 month since prior radiotherapy - At least 1 month since any prior anticancer therapy or adjuvant therapy - No other experimental treatment within 30 days prior to, during, and for 30 days after study therapy


NCT ID:

NCT00030615


Primary Contact:

Principal Investigator
Jeffrey Weber
University of Southern California


Backup Contact:

N/A


Location Contact:

Los Angeles, California 90033
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 11, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.